Videx data

Results of the company's Delta trial in Europe and Australian in more than 3,000 HIV-infected patients showed that combination treatment produced significant long-term survival benefit over AZT monotherapy, according to data presented at the Conference on Retroviruses and Opportunistic Infections in Washington.

Among patients who had not had an AIDS-defining event before the study, VIDEX plus AZT significantly delayed progression to AIDS or death, compared to AZT alone or ddC and AZT. ...